Want to see ABBV full AI Analyst Report?
ABBV Stock Chart & Stats
$265.79
$1.69(0.65%)
At close: 4:00 PM EDT
$265.79
$1.69(0.65%)
Day’s Range― - ―
52-Week Range$190.75 - $291.40
Previous CloseN/A
Volume289.56K
Average Volume (3M)4.66M
Market Cap
$499.53B
Enterprise Value$509.95B
Total Cash (Recent Filing)$6.57B
Total Debt (Recent Filing)$70.82B
Price to Earnings (P/E)80.4
Beta0.05
Next Earnings
Oct 30, 2026EPS Estimate
3.75Next Dividend Ex-DateN/A
Dividend Yield2.45%
Share Statistics
EPS (TTM)3.55
Shares Outstanding1,767,117,300
10 Day Avg. Volume5,895,203
30 Day Avg. Volume4,659,560
Financial Highlights & Ratios
PEG Ratio-77.13
Price to Book (P/B)-123.96
Price to Sales (P/S)6.63
P/FCF Ratio22.75
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue7.92
Enterprise Value/Gross Profit11.08
Enterprise Value/Ebitda24.07
Forecast
1Y Price Target
$286.67Price Target Upside7.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
EPS Forecast (FY)13.96
Revenue Forecast (FY)$67.62B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And MarginsAbbVie converts earnings into substantial operating and free cash flow, while maintaining strong gross profitability. This supports research investment, dividends, debt service, and business development, giving the company meaningful internal funding capacity over the coming quarters.
Growth In Key Immunology FranchisesRapid growth from SKYRIZI and RINVOQ is helping replace older products and gives AbbVie a stronger long-term immunology base. Continued market-share gains in psoriasis and IBD could support durable revenue expansion and improve franchise resilience.
Pipeline Expansion And Clinical ProgressABBV-466’s differentiated dual-targeting results add evidence that AbbVie can extend its immunology leadership through innovation. If later studies confirm these findings, the program could broaden the pipeline and create additional growth beyond current flagship therapies.
Bears Say
High Leverage And Negative EquityHeavy debt and negative equity reduce balance-sheet resilience and limit financial flexibility relative to periods when equity was positive. This can constrain capital allocation, increase sensitivity to financing costs, and make future acquisitions or investment more dependent on sustained cash generation.
Legacy Product ErosionDeclines in major legacy franchises create a persistent replacement burden for AbbVie’s newer products. Even strong growth in SKYRIZI and RINVOQ must continue for several periods to offset erosion, making portfolio transition a material execution challenge.
Acquisition-related Dilution And Financing CostsThe Apogee transaction expands the pipeline but introduces near-term earnings dilution, additional interest expense, and greater leverage management requirements. Benefits depend on successful development and commercialization, while financing costs can weigh on margins before the deal becomes accretive.
AbbVie News
ABBV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $190.75 and its highest was $291.40 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $499.53B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Oct 30, 2026 which is in 10 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Jul 31, 2026. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.605 by $0.045.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.73 which represents an annual dividend yield of 2.45%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 3.75.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,117,300 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $3.65 in its last earnings report, beating expectations of $3.605. Following the earnings report the stock price went down -2.514%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in ABBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$286.67 (7.85% Upside)
$286.67 (7.85% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 82%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.82%
12-Months-Change
Fundamentals
Return on Equity
-136.50%
Trailing 12-Months
Asset Growth
-1.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AbbVie
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
ABBV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum: above‑consensus results, double‑digit growth across key franchises (notably SKYRIZI and RINVOQ), multiple regulatory approvals, raised guidance, and a broadened pipeline via the Apogee deal. These positives are tempered by expected declines in legacy products (HUMIRA, IMBRUVICA), modest softness in some aesthetics lines, acquisition‑related dilution and IPR&D expense, and higher interest costs and FX headwinds. On balance the company presented durable growth drivers and ample financial flexibility despite near‑term dilution and known legacy declines.View all ABBV earnings summariesABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
ABBV Stock 12 Month Forecast
Average Price Target
$286.67
▲(7.85% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
20.80% Mutual Funds
1.07% Other Institutional Investors
55.42% Public Companies and Individual Investors